Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Biosign Investor Update

Biosign Investor Update

TORONTO, Feb. 4, 2013 /CNW/ - Biosign Technologies Inc. (TSXV: BIO) ("Biosign" or the "Company") announced several important achievements as it proceeds with its restructuring plan:

BIOSIGN APPOINTS SALES AGENT TO THE CANADIAN DENTAL MARKET. Dominion Medical Supply Inc ("Dominion"), a Dunville, ON-based specialty medical/dental sales agent, has been appointed to represent Biosign products to the Canadian dental market. Dominion represents a number of high-tech products, including disposable supplies as well as specialized magnifying lenses, to dentists in Ontario, Quebec and the Maritimes. The advanced nature of the products sold by Dominion typically involves extended interview time on each sales call to dentist and dental hygienist customers, which positions Dominion's team to detail the benefits offered by Biosign's health monitoring products.

BIOSIGN & DOMINION RE-LAUNCH "HEART FRIENDLY™ DENTIST" AND SUPPORT THE HEART & STROKE FOUNDATION DURING "HEART MONTH". In December 2012, Biosign acquired the assets of Bioanalytics Inc (see press release dated December 7th, 2012) including the brand name "Heart Friendly™" and associated marketing assets.

The Company announced the re-launch of the Heart Friendly™ Dentist program in Ontario. Dentists who enroll in the Heart Friendly™ Dentist program typically purchase a Biosign Pulsewave™ monitor for each exam room or dental hygiene station, and then also pay a monthly or annual fee for Biosign's Cloud Diagnostics™ readings and a free, printable Heart Friendly™ Health Report that they can print for each patient to take home. Dentists have commented that the Heart Friendly™ program gives them an additional valuable service to offer their patients, helps them differentiate their practice from their competition, and even assists them in identifying patients at immediate risk who may need medical attention. In a brief test-market campaign in 2012, Bioanalytics enrolled over 50 Toronto-area clinics in the Heart Friendly™ program, and many of these customers are now renewing their enrollment agreements with Biosign for either one or two year commitments.

During Heart Month (February 2013) Biosign has agreed to donate 5% of the net proceeds from each Toronto-area enrollment in the Heart Friendly™ Dentist program to the Heart & Stroke Foundation. Additionally, Heart Friendly™ Dentists will be able to distribute timely information from the Heart & Stroke Foundation to their patients along with a Heart Friendly™ Health Report, powered by Biosign.

DOMINION MEDICAL SUPPLY COMMENTS: Dominion co-founder Ms. Pam Wellings stated: "Dominion Medical is pleased to join Biosign as their sales agent to relaunch the Heart Friendly™ Dentist program in Ontario, particularly during Heart Month. Many dentist and hygienist customers are embracing the Heart Friendly™ approach to screening their patients, and dental customers appreciate receiving a Heart Friendly™ Health Report as a valuable part of their dental experience. We look forward to expanding the Heart Friendly program to other provinces we cover, including the Maritimes and Quebec, in the coming months."

MANAGEMENT COMMENTS: Biosign's CEO Mr. Robert Kaul commented: "Since our last Investor Update the Biosign team has continued to execute our recovery plan with excellent results. We have successfully added staff and channel distribution resources to execute revenue generation strategies, secured funding commitments to stabilize our finances, and refreshed our marketing materials. The re-launch of the Heart Friendly™ Dentist program along with an opportunity to support the Heart & Stroke Foundation is an important component of these renewed sales efforts, and the results, measured in the number of Dental Clinic customers that are re-enrolling after the 2012 market trial have been encouraging."

About Biosign Technologies Inc.

Biosign Technologies Inc. (TSXV: BIO) provides automated, computer enabled health information products. Key applications include the noninvasive monitoring of vital signs including blood pressure, pulse rate and breathing rate, enhanced with web services. The Company's Pulsewave™ medical device technology powers data collection for clinical decision support, self-care, wellness and disease management, while it's Healthanywhere™ software suite offers industry-leading remote patient monitoring solutions. The Company offers a number of cardiovascular screening programs for consumers under its Heart Friendly™ brand, including Heart Friendly™ Dentist. For more information on Biosign, please visit www.biosign.com

Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements, without limitation, may contain the words believes, expects, anticipates, estimates, intends, plans, or similar expressions. Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions and Biosign's actual results could differ materially from those anticipated. Forward looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. In the context of any forward-looking information please refer to risk factors detailed in, as well as other information contained in, Biosign's filings with Canadian securities regulators (www.sedar.com).

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

SOURCE: Biosign Technologies Inc.

Biosign Contact Information
Robert Kaul
Chief Executive Officer
Biosign Technologies
Phone: (416) 218-9800 ext. 201
Email: ceo@biosign.com